XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net (loss) income $ 8,069 $ (16,552)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation 2,817 2,633
Amortization of software and intangible assets 2,688 1,688
Amortization of debt issuance costs 409 1,005
Share-based compensation 2,705 16,906
Deferred income taxes (684) 7,499
Provision for inventory excess and obsolescence 1,933 325
Other 571 81
Change in assets and liabilities:    
Receivables 7,931 653
Inventories 10,567 (8,662)
Accounts payable 175 (1,657)
Accrued employee compensation 5,313 343
Accrued liabilities (147) 164
Accrued Sponsor interest and payables   (5,457)
Other assets and liabilities (528) (1,561)
Net cash (used in ) provided by operating activities 41,819 (2,592)
Cash flows from investing activities:    
Purchase of property and equipment (2,432) (2,535)
Purchase of software (921) (872)
Cash paid for acquisition (334) (2,000)
Net cash used in investing activities (3,687) (5,407)
Cash flows from financing activities:    
Proceeds from issuance of revolver debt 10,000  
Repayment of term loan (7,500) (27,837)
Repayment of revolver debt (10,000) (10,000)
Payment of debt issuance costs   (336)
Proceeds from initial public offering, net of underwriting commission and fees   65,988
Taxes paid from shares withheld 31 (802)
Proceeds from share option exercises 163  
Payment of deferred offering costs   (4,435)
Net cash provided by (used in) financing activities (7,306) 22,578
Effect of exchange rate on cash (52) (70)
Net increase in cash 30,774 14,509
Cash, beginning of period 19,346 4,441
Cash, end of period 50,120 18,950
Supplemental disclosure of cash flow information:    
Income taxes paid 1,626 1,432
Interest paid $ 3,138 5,270
Significant non-cash activities:    
Issuance of shares for unreturned capital and accumulated yield   49,252
Deferred offering costs included in accrued liabilities   $ 179